When a company offers "unspecified remedies" to regulators, what it's really saying is: We hear your concerns, and we're willing to make concessions to get this deal across the finish line.

That's exactly where Baker Hughes ($BKR) finds itself with its proposed $13.6 billion acquisition of Chart Industries ($GTLS), as reported on June 22, 2026. For merger arbitrage traders, this development is both a signal and a puzzle—and understanding the difference could determine whether this spread widens or collapses.

The Language of Regulatory Compromise

Let's decode what "offering remedies" actually means in the merger playbook. In regulatory parlance, remedies are the structural or behavioral commitments a buyer makes to address antitrust or competition concerns. They typically fall into three buckets:

• Divestitures: Selling off overlapping business units or assets to eliminate competitive overlap
• Behavioral commitments: Contractual promises to maintain pricing, supply, or licensing practices
• Asset sales or licensing: Transferring specific technologies, patents, or customer contracts to competitors

The fact that Baker Hughes is offering remedies—even if the specifics remain undisclosed—signals that regulators (likely the DOJ or FTC, given the energy equipment and industrial gas overlap between the two companies) have flagged legitimate competitive concerns. This isn't a rubber-stamp situation. This is a negotiation.

Why This Deal Matters (and Why Regulators Care)

The strategic logic is compelling: Baker Hughes acquiring Chart Industries would reshape the energy technology and LNG equipment landscape. Chart is a heavyweight in cryogenic equipment and liquefied natural gas infrastructure—precisely where Baker Hughes wants to deepen its footprint as energy markets evolve. The combination creates a formidable competitor in a sector where scale and technology integration matter enormously.

But that's exactly why regulators are paying attention. In energy equipment markets, overlapping product lines, shared customer bases, and technical expertise create antitrust red flags. The remedies Baker Hughes is offering suggest the deal team has identified where those overlaps are most acute—and where divestitures or behavioral commitments could address them.

The Merger Arb Spread: Reading the Tea Leaves

For sophisticated traders, the real story is in the spread—the gap between Chart's current trading price and the $13.6 billion offer value. A wider spread reflects higher deal-completion risk. A tightening spread suggests improving odds.

The offer of remedies cuts both ways. On one hand, it signals Baker Hughes is serious about clearing regulatory hurdles and willing to make concessions. That's positive for deal completion. On the other hand, the fact that remedies are needed at all means the deal wasn't a slam dunk from the regulatory perspective. The "unspecified" nature of those remedies adds another layer of uncertainty—traders don't yet know how material the concessions will be or how they'll affect deal economics.

The spread dynamics ultimately reflect this tension: Is this a deal that's moving toward closure with manageable regulatory conditions, or are we watching the early stages of a deal that could face material restructuring or, in the worst case, termination?

The Broader Regulatory Environment

Context matters. Large energy-sector M&A in 2026 faces an intensely scrutinized regulatory environment. Antitrust enforcement remains active, and deals involving critical infrastructure, energy transition technologies, and industrial consolidation draw particular attention. Baker Hughes and Chart Industries operate in precisely those spaces—energy equipment, LNG, and the infrastructure supporting the global energy transition.

Against this backdrop, the willingness to offer remedies may indicate Baker Hughes has done its homework and believes the deal is salvageable with targeted concessions. Alternatively, it could signal that regulators have signaled serious concerns and Baker Hughes is testing whether remedies can bridge the gap.

Deal Completion Risk: The Downside Scenario

If the deal fails, Chart Industries shareholders face a significant repricing event. The stock would likely retreat sharply from offer-implied valuations, reflecting the loss of the acquisition premium and underlying business concerns that may have prompted the deal in the first place. For Baker Hughes, a failed deal represents lost strategic opportunity and potential shareholder disappointment—though the impact would likely be more muted given BKR's broader portfolio.

The path forward hinges on whether the remedies Baker Hughes is offering prove sufficient to satisfy regulatory concerns. Until those remedies are specified and formally accepted, the deal remains in limbo—and that uncertainty is precisely what merger arb spreads are designed to price.